MA32498B1 - Compositions pharmaceutiques de rosuvastatine calcium - Google Patents

Compositions pharmaceutiques de rosuvastatine calcium

Info

Publication number
MA32498B1
MA32498B1 MA33550A MA33550A MA32498B1 MA 32498 B1 MA32498 B1 MA 32498B1 MA 33550 A MA33550 A MA 33550A MA 33550 A MA33550 A MA 33550A MA 32498 B1 MA32498 B1 MA 32498B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
rosuvastatin calcium
sodium carbonate
anhydrous sodium
rosuvastatin
Prior art date
Application number
MA33550A
Other languages
Arabic (ar)
English (en)
Inventor
Farhad Sayyad Farshi
Recep Avci
Serdar Apari
Original Assignee
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of MA32498B1 publication Critical patent/MA32498B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques de rosuvastatine ou ses sels pharmaceutiquement acceptables, notamment le sel de calcium avec du carbonate de sodium anhydre qui a des effets sur les profils de dissolution dans un milieu hcl 0,1 n, à condition que l'utilisation de carbonate de sodium anhydre ait lieu dans la plage allant d'environ 0,5 % à environ 2 % en poids.
MA33550A 2008-06-27 2011-01-21 Compositions pharmaceutiques de rosuvastatine calcium MA32498B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/052595 WO2009156796A1 (fr) 2008-06-27 2008-06-27 Compositions pharmaceutiques de rosuvastatine calcium

Publications (1)

Publication Number Publication Date
MA32498B1 true MA32498B1 (fr) 2011-07-03

Family

ID=40386506

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33550A MA32498B1 (fr) 2008-06-27 2011-01-21 Compositions pharmaceutiques de rosuvastatine calcium

Country Status (19)

Country Link
US (1) US20110098315A1 (fr)
EP (1) EP2306982B1 (fr)
JP (1) JP2011525901A (fr)
KR (1) KR101283147B1 (fr)
AU (1) AU2008358622A1 (fr)
BR (1) BRPI0822782A2 (fr)
CA (1) CA2728539A1 (fr)
DK (1) DK2306982T3 (fr)
EA (1) EA201170101A1 (fr)
ES (1) ES2535106T3 (fr)
GE (1) GEP20135735B (fr)
IL (1) IL210102A0 (fr)
MA (1) MA32498B1 (fr)
MX (1) MX2010013834A (fr)
PT (1) PT2306982E (fr)
TN (1) TN2010000585A1 (fr)
TR (1) TR201101807T2 (fr)
WO (1) WO2009156796A1 (fr)
ZA (1) ZA201009057B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609138B2 (en) * 2010-06-30 2013-12-17 Mochida Pharmaceutical Co., Ltd. ω3 fatty acid compound preparation
RO129060B1 (ro) * 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN107072997A (zh) 2014-11-11 2017-08-18 盐野义制药株式会社 含有对光不稳定的药物的多层片剂
JP6108635B2 (ja) * 2015-05-14 2017-04-05 ダイト株式会社 ロスバスタチン含有口腔内速崩壊錠
HRP20251674T1 (hr) 2019-07-31 2026-02-13 Intas Pharmaceuticals Ltd. Farmaceutski pripravak koji sadrži inhibitore hmg coa reduktaze i fenofibrat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU2003227691B2 (en) * 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
JP4839221B2 (ja) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Ｈｄｌを高める併用療法用複合物
WO2006134604A1 (fr) * 2005-06-15 2006-12-21 Hetero Drugs Limited Composition combinant un inhibiteur d’absorption du cholestérol et un inhibiteur de la 3-hydroxy-3-méthylglutaryl-coenzyme a (hmg-coa) réductase
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles
WO2008005543A2 (fr) * 2006-07-06 2008-01-10 Teva Pharmaceutical Industries Ltd. Compositions à pharmacocinétique contrôlée
WO2008062476A2 (fr) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Composition pharmaceutique comprenant de la rosuvastatine ou un sel de qualité pharmaceutique de cette substance

Also Published As

Publication number Publication date
IL210102A0 (en) 2011-02-28
ZA201009057B (en) 2012-01-25
BRPI0822782A2 (pt) 2015-09-29
TN2010000585A1 (en) 2012-05-24
PT2306982E (pt) 2015-05-18
KR20110027711A (ko) 2011-03-16
CA2728539A1 (fr) 2009-12-30
WO2009156796A1 (fr) 2009-12-30
JP2011525901A (ja) 2011-09-29
GEP20135735B (en) 2013-01-25
EP2306982B1 (fr) 2015-01-07
AU2008358622A1 (en) 2009-12-30
ES2535106T3 (es) 2015-05-05
KR101283147B1 (ko) 2013-07-05
DK2306982T3 (en) 2015-04-20
MX2010013834A (es) 2011-02-21
EA201170101A1 (ru) 2011-08-30
US20110098315A1 (en) 2011-04-28
EP2306982A1 (fr) 2011-04-13
TR201101807T2 (tr) 2012-02-21

Similar Documents

Publication Publication Date Title
MA32498B1 (fr) Compositions pharmaceutiques de rosuvastatine calcium
LU92666I2 (fr) Dasabuvir ou un sel qui en dérive, y compris dasabuvir sodium monohydrate
LU92595I2 (fr) Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium
MX2009013255A (es) Matriz de solidificacion que incluye una sal de un acido mono-, di- o tri-carboxilico saturado de cadena recta.
MA33058B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan avec stabilite amelioree
EP1962827A4 (fr) Compositions pharmaceutiques contenant des combinaisons d'inhibiteurs de la dipeptidylpeptidase 4 avec de la métformine
WO2009058798A3 (fr) Forme posologique se désintégrant dans la bouche et ses utilisations
TNSN08505A1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
MY151295A (en) Pyrimidyl indoline compound
EP2189481A4 (fr) Polymère contenant du fluor et modificateur de surface le contenant en tant qu'ingrédient actif
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
EP2197858A4 (fr) Composé de 1,3,5-triazine-2,4,6-triamine ou son sel pharmaceutiquement acceptable, et composition pharmaceutique le comprenant
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
DK2151241T3 (da) Stabilt fast præparat, omfattende 4,5-epoxymorphinanderivat
WO2008062476A3 (fr) Composition pharmaceutique comprenant de la rosuvastatine ou un sel de qualité pharmaceutique de cette substance
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
ATE554770T1 (de) Therapeutisches mittel gegen entzündliche darmerkrankungen
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
UY32126A (es) Composición farmacéutica sólida
CL2007003189A1 (es) Compuestos derivados de indol y benzofurano; composicion farmaceutica; y uso para el tratamiento o la prevencion de la enfermedad de alzheimer.
EA201300715A1 (ru) Бульонный кубик
WO2008026048A3 (fr) Compositions pharmaceutiques injectables stables de docétaxel
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
PE20020351A1 (es) Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof